Pelabresib is under clinical development by MorphoSys and currently in Phase III for Post-Polycythemia Vera Myelofibrosis (PPV-MF). According to GlobalData, Phase III drugs for Post-Polycythemia Vera Myelofibrosis (PPV-MF) have an 80% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Pelabresib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Pelabresib overview
Pelabresib (CPI-0610) is under development for the treatment of acute myelocytic leukemia (AML, Acute Myeloblastic Leukemia), myelodysplastic syndrome or myelodysplastic/myeloproliferative neoplasms myelofibrosis, primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis. The drug candidate is administered orally and is a new molecular entity. It acts by targeting bromodomain and extra-terminal (BET) proteins (BRD2, BRD3, BRD4, and BRDT). It was also under development for the treatment of non-Hodgkin lymphomas including diffuse large cell B-cell lymphoma (DLBCL), follicular lymphoma, Hodgkin lymphoma, multiple myeloma.
MorphoSys overview
MorphoSys is a commercial-stage biopharmaceutical company that develops monoclonal antibodies for therapeutic and research applications, with a focus on the treatment of cancer and autoimmune diseases. The company’s product pipeline includes tafasitamab, pelabresib, cpi-0209, gantenerumab, otilimab, ianalumab, abelacimab, felzartamab, setrusumab, NOV-8, NOV-14 and MOR210. Its Tafasitamab is a humanized Fc-modified cytolytic CD19 targeting monoclonal antibody directed against CD19 in clinical development for the treatment of B cell malignancies. The company provides clinical trials for cancer and inflammatory disorders. MorphoSys also conducts research and development activities with pharmaceutical and biotechnology companies. The company owns a regional licensing agreement to develop and commercialize products. It operates in the US. MorphoSys is headquartered in Planegg, Bayern, Germany.
For a complete picture of Pelabresib’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
Smarter leaders trust GlobalData
Premium Insights Likelihood of Approval and Phase Transition Success Rate Model - Pelabresib in Post-Polycythemia Vera Myelofibrosis (PPV-MF)
Premium Insights
The gold standard of business intelligence.
